Heart rhythm · 2026
Management of engraftment arrhythmias associated with human-induced pluripotent stem cell-derived cardiomyocytes transplantation.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Zhang Aixue, Liu Yufan, Wei Yanwei, Zhang Yunqiang, Chen Yuanlu, Wang Yongde, Wang Jianyong, Guo Zhipeng, Zhang Jianliang, Fu Yue, Yang Qin, Liu Xiaocheng, Jing Rui
Аннотация
BACKGROUND: Intramyocardial injection of human induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs) is a promising cell replacement therapy for myocardial infarction, but engraftment arrhythmias (EAs) posttransplantation hinder their clinical translation.
OBJECTIVE: This study aims to analyze EA characteristics after hiPSC-CM transplantation and to identify risk factors associated with the occurrence of EAs.
METHODS: This study included patients undergoing coronary artery bypass grafting (CABG) combined with hiPSC-CM transplantation (experimental group) or isolated CABG (control group) at our hospital between November 2023 and November 2025. Patients in the experimental group were assigned to low- and high-dose groups (0.5 × 108 and 1.5 × 108 cells). EA characteristics were analyzed and compared between the 2 subgroups. Univariate logistic regression was performed to identify risk factors for EAs.
RESULTS: A total of 24 patients in the experimental group were enrolled, 13 (54.2%) of whom developed EAs originating from the cell injection site (localized by electrocardiogram QRS morphology). Initially, EAs were paroxysmal (heart rate: 55-96 bpm, 72.15 ± 9.77 bpm), progressing to sustained episodes over hours with increased heart rate (max 111-185 bpm, 146.00 ± 21.02 bpm) and R-R interval variability. No hemodynamic abnormalities were detected in any patient during EA episodes. Atrial pacing and electrical cardioversion reduced EA rate but failed to terminate EAs. EA incidence was significantly higher in the high-dose than low-dose group (10/12 [83.3%] vs 3/12 [25.0%], P = .012). Univariate logistic regression showed hiPSC-CM dose was significantly associated with EA occurrence (odds ratio, 15.00; 95% confidence interval, 2.02-111.17; P = .008).
CONCLUSION: The occurrence of EAs was likely driven by an automaticity mechanism, and hiPSC-CM transplantation dose was significantly correlated with EA incidence.
OBJECTIVE: This study aims to analyze EA characteristics after hiPSC-CM transplantation and to identify risk factors associated with the occurrence of EAs.
METHODS: This study included patients undergoing coronary artery bypass grafting (CABG) combined with hiPSC-CM transplantation (experimental group) or isolated CABG (control group) at our hospital between November 2023 and November 2025. Patients in the experimental group were assigned to low- and high-dose groups (0.5 × 108 and 1.5 × 108 cells). EA characteristics were analyzed and compared between the 2 subgroups. Univariate logistic regression was performed to identify risk factors for EAs.
RESULTS: A total of 24 patients in the experimental group were enrolled, 13 (54.2%) of whom developed EAs originating from the cell injection site (localized by electrocardiogram QRS morphology). Initially, EAs were paroxysmal (heart rate: 55-96 bpm, 72.15 ± 9.77 bpm), progressing to sustained episodes over hours with increased heart rate (max 111-185 bpm, 146.00 ± 21.02 bpm) and R-R interval variability. No hemodynamic abnormalities were detected in any patient during EA episodes. Atrial pacing and electrical cardioversion reduced EA rate but failed to terminate EAs. EA incidence was significantly higher in the high-dose than low-dose group (10/12 [83.3%] vs 3/12 [25.0%], P = .012). Univariate logistic regression showed hiPSC-CM dose was significantly associated with EA occurrence (odds ratio, 15.00; 95% confidence interval, 2.02-111.17; P = .008).
CONCLUSION: The occurrence of EAs was likely driven by an automaticity mechanism, and hiPSC-CM transplantation dose was significantly correlated with EA incidence.